Ann: Half-Year Results Announcement, page-7

I have not read of RGS making a direct comparison with Viralytics - however, they are both involved in immuno-oncology space, which is very hot at the moment - VLA is further down the development path than RGS's RGSH4K - however RGS will be reporting in a few months on its first in man autologous phase 1 ACTIVATE trial - RGS sees RGSH4K as a unique product in immuno-oncology. RGS had excellent results in its animal trials in this area with a similar product.